|
08 Nov 2019 |
Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers
|
|
08 Nov 2019 |
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial
|
|
08 Nov 2019 |
Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar to Rituxan® (rituximab) in the United States
|
|
08 Nov 2019 |
Alpine Immune Sciences Presents New Preclinical Data at The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
|
|
08 Nov 2019 |
AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML
|
|
08 Nov 2019 |
AvantGen Enters a Strategic Collaboration Agreement to Develop Novel Anti-Cancer Therapeutic With Its NK Cell Engager Technology
|
|
08 Nov 2019 |
F-star Presents New Data on OX40/CD137 Tetravalent Bispecific Antibody at the SITC 2019 Annual Meeting
|
|
06 Nov 2019 |
Coherus Acquires Commercial Rights for Leading Lucentis Biosimilar in the United States
|
|
06 Nov 2019 |
Samsung Bioepis Enters into Commercialization Agreement for Next-Generation Biosimilar Candidates
|
|
06 Nov 2019 |
Compugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of COM701 in Patients with Advanced Solid Tumors at SITC 2019
|
|
06 Nov 2019 |
Compugen Presents Preclinical Data for COM902 Anti-TIGIT Program at SITC 2019
|
|
05 Nov 2019 |
SciRhom Initiates First-In-Class Antibody Development Program to Treat Major Autoimmune Diseases
|
|
04 Nov 2019 |
Compugen Announces FDA Clearance of IND Application for COM902
|
|
04 Nov 2019 |
Harbour BioMed Announces Initiation of First-in-human Study of Next-generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors
|
|
01 Nov 2019 |
Pinteon Therapeutics Launches Phase 1 Trial of Novel Tau Antibody that Targets a Potent Driver of Neurodegenerative Disease
|
|
01 Nov 2019 |
Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis
|
|
31 Oct 2019 |
Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug Conjugate, DS-7300, in Collaboration with Sarah Cannon Research Institute
|
|
30 Oct 2019 |
CytomX Therapeutics Announces Initiation of Phase 2 Clinical Trial Evaluating the Anti-PD-L1 Probody CX-072 in Combination with YERVOY® in Patients with Relapsed or Refractory Melanoma
|
|
30 Oct 2019 |
FDA Accepts Genentech’s Biologics License Application for Satralizumab for Neuromyelitis Optica Spectrum Disorder
|
|
29 Oct 2019 |
Harpoon Therapeutics Presents Preclinical Data for HPN328, a DLL3-targeting T Cell Engager, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
|
|
29 Oct 2019 |
Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer
|
|
29 Oct 2019 |
Intravenous Benlysta is the first biologic treatment to be approved for children with lupus in Europe
|
|
29 Oct 2019 |
Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis
|
|
29 Oct 2019 |
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
|
|
29 Oct 2019 |
MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility
|
